TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed breast cancer resected at time of original diagnosis~  * Stage I-III disease~* Candidate for 1 of the following adjuvant chemotherapy regimens:~  * FEC (fluorouracil, epirubicin hydrochloride, and cyclophosphamide) every 21 or 28 days~ * CMF (cyclophosphamide, methotrexate, and fluorouracil) every 28 days~ * A→CMF (doxorubicin hydrochloride followed by CMF)~ * EC→P (epirubicin hydrochloride and cyclophosphamide every 21 days followed by paclitaxel every 21 days)~ * FEC→P (FEC every 21 days followed by paclitaxel every 21 days)~ * EC→D (EC every 21 days followed by docetaxel every 21 days)~ * AC (doxorubicin hydrochloride and cyclophosphamide) every 21 days~ * AC→P (AC every 21 days followed by paclitaxel every 21 days)~ * E→CMF (epirubicin hydrochloride followed by CMF every 28 days)~* No evidence of metastases or localized or distant recurrence~  * Investigation to exclude metastases required for any suspicious manifestation~* Premenopausal, defined as the presence of active menstrual cycles or normal menses within six weeks before initiation of chemotherapy~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Female~* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or adequately treated in situ carcinoma of the cervix~* No history of noncompliance to medical regimens or patients who are considered potentially unreliable~* Not pregnant or nursing~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy and/or radiotherapy for cancer or non-neoplastic disease~* No other concurrent hormonal therapy except for tamoxifen

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Platelet- and Extracellular Vesicle-rich Plasma in Chronic Postsurgical Temporal Bone Inflammations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic otitis media, defined as a presence of at least 1 of the following: visible ear discharge, indirect signs of ear discharge (e.g. on a pillow, clothes), ear itching, the sensation of ear fullness, clinical signs of acute exacerbation of chronic otitis media during an otomicroscopic examination.~* non-cholesteatomatous chronic otitis media despite prior standard conservative treatment~* non-cholesteatomatous chronic otitis media despite prior surgical treatment~Exclusion Criteria:~* the presence or suspicion of cholesteatoma~* infection of venepuncture site~* pregnancy~* breastfeeding~* long-term treatment with antimicrobial drugs~* long-term treatment with immunosuppressant drugs~* the presence of systemic infectious disease~* the presence of an autoimmune disease~* the presence of cancer~* receiving other types of experimental treatment for chronic otitis media

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PVRP treated participants (Type: EXPERIMENTAL): Participants will receive PVRP in the chronically inflamed radical cavity at the baseline evaluation (day 0) and 1 month later (1. follow-up). There will be 2 additional follow-ups with a 1-month interval.
- Standardly treated participants (Type: ACTIVE_COMPARATOR): Participants will receive standard conservative measures for the chronically inflamed radical cavity at the baseline evaluation (day 0), 1 month later (1. follow-up), 2 months later (2. follow-up) and 3 months later (3. follow-up).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 18 years or older.~* Patient suffering from mild to moderate active proctitis or distal proctosigmoiditis (MAYO score ≥ 3 and ≤ 10) at inclusion based on clinical and endoscopic findings within 6 months before study inclusion.~* Patient with evidence of endoscopic active proctitis or distal proctosigmoiditis (Montreal classification E1 or E2 defined by an involvement not exceeding 25 cm from the anal margin) within 6 months before study inclusion.~* Treatment of the current flare with Pentasa® to induce a remission initiated by the patient, the general practitioner or the gastroenterologist, during the inclusion visit or during the week before the inclusion visit.~* Patient having received oral and written information on the study, without any objections for the use of his/her personal data, and having signed a written Informed Consent Form.~Exclusion Criteria:~* Patient included in an interventional study assessing treatment for active proctitis or distal proctosigmoiditis.~* Patient with left sided, colitis or pancolitis.~* Patient with severe proctitis (MAYO score ≥ 11 at inclusion).~* Patient previously treated with biologics.~* Patient treated with immunosuppressive within 1 month before study inclusion.~* Patient treated with corticosteroids within 2 weeks before study inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mesalazine (Type: None): Treatment according to standard clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically-confirmed adenocarcinoma of the colon or rectum in patients with unresectable metastatic (M1) disease~* Patients with at least 1 uni-dimensionally measurable lesion of at least 10 mm per modified Response Evaluation Criteria in Solid Tumors (RECIST) guidelines~* Wild-type KRAS tumor status confirmed by an Amgen approved central laboratory or an experienced laboratory (local laboratory) per local regulatory guidelines using a validated test method~* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1~* Men or women 18 years of age or older~* Adequate hematologic, renal, hepatic, metabolic, and coagulation function~Exclusion Criteria:~* History of prior or concurrent central nervous system (CNS) metastases~* Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic colorectal carcinoma~* Clinically significant cardiac disease~* Clinically significant peripheral sensory neuropathy~* Active inflammatory bowel disease~* Recent gastroduodenal ulcer to be active or uncontrolled~* History of interstitial lung disease~* Recent pulmonary embolism, deep vein thrombosis, or other significant venous event~* Pre-existing bleeding diathesis and/or coagulopathy with exception of well-controlled anticoagulation therapy~* Recent major surgical procedure, open biopsy, or significant traumatic injury not yet recovered from prior major surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab Plus mFOLFOX6 (Type: EXPERIMENTAL): Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2) and 5-fluorouracil (5-FU) (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
- Bevacizumab Plus mFOLFOX6 (Type: ACTIVE_COMPARATOR): Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2), followed by 5-FU (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* male \& female subjects greater than or equal to 18 years of age with newly diagnosed or relapsing mild to moderate ulcerative colitis~* general medical assessment satisfactory and no clinically significant and relevant abnormalities~Exclusion Criteria:~* severe ulcerative colitis~* subject in relapse for \> 6 weeks~* use of systemic or rectal steroids within last 4 weeks prior to baseline~* subjects with proctitis, previous colonic surgery, Crohn's disease, bleeding disorders, active ulcer disease~* subjects hypersensitive to salicylates/aspirin~* subjects with moderate or severe renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hypertension~* Elevated urinary protein levels~* Confirmed type 2 diabetes~Exclusion Criteria:~* Certain diseases~* Uncontrolled diabetes~* Type 1 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Major Inclusion Criteria:~* Signed informed consent~* Male or female patients, 18 to 75 years of age~* Confirmed clinicopathological diagnosis of EoE according to established diagnostic criteria:~(A) Clinical symptoms of esophageal dysfunction (B) Peak eosinophils ≥ 15 in at least 1 high-power field (hpf)~- Active symptomatic and histological EoE at baseline~Major Exclusion Criteria:~* Clinically and endoscopically suspicion for gastroesophageal reflux disease, achalasia, or sklerodermia~* Gastroesophageal reflux disease and PPI-responsive esophageal eosinophilia~* Other clinical evident causes than EoE for esophageal eosinophilia~* Any concomitant esophageal disease and relevant gastro-intestinal disease (celiac disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or fungal infection)~* Any relevant systemic disease (e.g., AIDS, active tuberculosis)~* Abnormal hepatic function at screening visit, liver cirrhosis, or portal hypertension~* Abnormal renal function at screening~* History of cancer in the last five years (except for non-metastatic cancers, e.g., basalioma)~* History of esophageal surgery at any time or of esophageal dilation procedures within the last 8 weeks prior to screening visit~* Upper gastrointestinal bleeding within 8 weeks prior to screening visit~* Concomitant, or within the 4 weeks prior to screening visit, treatment with systemic therapies for any reason that may affect assessment of primary and secondary endpoints, i.e., systemic glucocorticoids, histamine antagonists, mast cell stabilizers, leukotriene receptor antagonists, biologics, or immunosuppressants~* Concomitant, or within the 2 weeks prior to screening visit, treatment with topical therapies for any reason that may affect assessment of primary and secondary endpoints, i.e., topical glucocorticoids or inhaled sodium cromoglycate~* Installation of dietary restrictions within 4 weeks prior to screening visit or during treatment~* Intake of grapefruit containing food or beverages during the treatment with study medication~* Known intolerance/hypersensitivity to study drug~* Existing or intended pregnancy or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Low dose budesonide tablet (Type: EXPERIMENTAL): None
- High dose budesonide tablet (Type: EXPERIMENTAL): None
- High dose budesonide suspension (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CF.~* Age ≥ 12 years at the Screening Visit.~* Forced expiratory volume in 1 second (FEV1) ≥ 70 % predicted at the Screening Visit if \< 18 years old, and ≥ 60 % predicted at Screening Visit if ≥ 18 years old.~* Clinically stable with no significant changes in health status within the 7 days prior to and including the Screening Visit.~* Current treatment with elexacaftor/tezacaftor/ivacaftor (ETI) for at least the 90 days prior to and including the Screening Visit and willing to continue daily use for the duration of the study.~* Currently taking hypertonic saline (at least 3%) for at least the 90 days prior to and including the Screening Visit and willing to continue daily use for the 2-week screening period.~Exclusion Criteria:~* Active smoking or vaping.~* Use of an investigational drug within 28 days prior to and including the Screening Visit.~* Changes to chronic therapy (e.g., ibuprofen, azithromycin, inhaled tobramycin, aztreonam lysine) within 28 days prior to and including the Screening Visit. This includes new airway clearance routines.~* Acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids for respiratory tract symptoms within 7 days prior to and including the Screening Visit.~* Chronic use of systemic corticosteroids at a dose equivalent to ≥ 10mg per day of prednisone within 28 days prior to and including the Screening Visit.~* Antibiotic treatment for nontuberculous mycobacteria (NTM) within 28 days prior to and including the Screening Visit.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HS-Discontinue (Type: EXPERIMENTAL): Discontinuation of current hypertonic saline (HS) therapy
- HS-Continue (Type: ACTIVE_COMPARATOR): Continuation of current hypertonic saline (HS) therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents or guardians can and will comply with the requirements of the protocol.~* A male or female between, and including, 2 and 10 years of age at the time of vaccination.~* Written informed consent obtained from the parent or guardian of the subject.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~* Previously completed routine childhood vaccinations to the best of his/her parents'/guardians' knowledge.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine.~* Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W-135 and/or Y (for subjects below 6 years) or within the last five previous years (for subjects 6 years old or above).~* Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroups A, C, W-135 and/or Y.~* Previous vaccination with tetanus toxoid within the last month.~* History of meningococcal disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination..~* History of reactions or allergic disease likely to be exacerbated by any component of the vaccine(s).~* Major congenital defects or serious chronic illness.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Nimenrix Group (Type: EXPERIMENTAL): Subjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
- Mencevax ACWY Group (Type: ACTIVE_COMPARATOR): Subjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Midazolam for Treatment of Anxiety in Children Undergoing Suturing in the Pediatric Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children 2-12 years requiring laceration repair using suturing and use of injected lidocaine~Exclusion Criteria:~* Administration in ER of analgesia or sedation other than acetaminophen or ibuprofen prior to enrolment~* ASA of III or greater~* Multi-system trauma~* Severe neurologic impairment or non-verbal autism, known allergy/hypersensitivity to lidocaine or midazolam~* Parent/guardian does not speak one of French or English~* No parent/guardian present during procedure

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Intranasal Saline (Type: PLACEBO_COMPARATOR): 0.08ml/kg of saline to a maximum of 2ml intranasally with an atomizer MAD-300
- Intranasal Midazolam (Type: ACTIVE_COMPARATOR): 0.08ml/kg (0.4mg/kg of 5mg/ml IV solution) intranasal midazolam, to a maximum of 2ml (10mg), with an atomizer MAD-300

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. CAD diagnosis defined by the combination of -~   1. Chronic hemolysis~  2. Cold agglutinin titer 64 or higher~  3. Positive direct antiglobulin test when performed with polyspecific antiserum, negative (or only weakly positive) with anti-IgG, and strongly positive with anti-C3d~2. The presence of a clonal B-cell lymphoproliferative disorder defined by -~   1. Monoclonal band by serum electrophoresis with immunofixation, and/or~  2. CD20 positive lymphocyte population with cellular kappa/lamda-ratio higher than 3.5 or less than 0.9, using flowcytometric immunophenotyping of bone marrow aspirates~3. Indication for therapy, i.e. significant anemia and/or considerable cold-induced circulatory symptoms~4. Written informed consent~Exclusion Criteria:~1. An aggressive lymphoma~2. Non-lymphatic malignant disease other than basal cell carcinoma of the skin. A history of probably cured cancer is not an exclusion criterion.~3. Known HIV infection~4. Acute or chronic hepatitis B or C~5. Liver failure or active parenchymal liver disease. Bilirubin levels higher than 51 mol/L (3.0 mg/dL) when due to hepatic impairment. Elevated serum bilirubin level due to hemolysis is not an exclusion criterion.~6. Pregnancy or breast-feeding~7. Patients of childbearing age who are not willing to use safe contraception during the entire study period and 6 months following its cessation~8. All contraindications to the study drugs will be regarded as exclusion criteria.~9. Age below 18 years~10. Inability to cooperate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): Bendamustine, Rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete